CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2013--
Verastem, Inc., (NASDAQ: VSTM), a clinical-stage biopharmaceutical
company focused on discovering and developing drugs to treat cancer by
the targeted killing of cancer stem cells, announced that financial
results for the year ended December 31, 2012, will be released before
the market opens on Wednesday, March 27, 2013. The Verastem management
team will host a conference call discussing the Company's financial
results, recent developments and management’s outlook for 2013 on
Wednesday, March 27, 2013, at 8:00 AM (ET). The call can be accessed by
dialing 1-866-700-6293 five minutes prior to the start of the call and
providing the passcode 40173121. A replay will be available
approximately two hours after the completion of the call and can be
accessed by dialing 1-888-286-8010 and providing the passcode 58773105.
The replay will be available for two weeks from the date of the live
call.
The live, listen-only webcast of the conference call can be accessed by
visiting the investors section of the Company’s website at www.verastem.com.
A replay of the webcast will be archived on the Company’s website for
two weeks following the call.
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical
company focused on discovering and developing drugs to treat cancer by
the targeted killing of cancer
stem cells. Cancer stem cells are an underlying cause of tumor
recurrence and metastasis. Verastem is developing small molecule
inhibitors of signaling pathways that are critical to cancer stem cell
survival and proliferation: FAK, PI3K/mTOR and Wnt. For more
information, please visit www.verastem.com.
Forward-looking statements:
Any statements in this press release about future expectations, plans
and prospects for the Company constitute forward-looking statements.
Actual results may differ materially from those indicated by such
forward-looking statements. The Company anticipates that subsequent
events and developments will cause the Company’s views to change.
However, while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
Source: Verastem, Inc.
Verastem, Inc.
Investor contact:
Brian Sullivan,
617-252-9314
bsullivan@verastem.com
or
Media
contact:
Kari Watson, 781-235-3060
kwatson@macbiocom.com
